OvaScience Inc. (NASDAQ:OVAS) was down 5.8% during mid-day trading on Thursday . The company traded as low as $5.12 and last traded at $5.16, with a volume of 144,221 shares trading hands. The stock had previously closed at $5.48.

A number of equities research analysts have issued reports on OVAS shares. Oppenheimer Holdings Inc. restated a “hold” rating on shares of OvaScience in a research note on Monday, April 25th. Leerink Swann reiterated a “hold” rating and set a $7.00 price objective (up from $6.00) on shares of OvaScience in a research note on Sunday, May 8th. Finally, Credit Suisse Group AG reiterated a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $12.37.

The firm’s market cap is $137.73 million. The company has a 50-day moving average price of $5.35 and a 200-day moving average price of $7.16.

OvaScience (NASDAQ:OVAS) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.08. During the same period in the previous year, the business posted ($0.65) EPS. The business earned $0.15 million during the quarter, compared to the consensus estimate of $0.14 million. The business’s revenue was up 630.0% compared to the same quarter last year. Equities analysts anticipate that OvaScience Inc. will post ($3.14) earnings per share for the current year.

In other OvaScience news, CEO Michelle Dipp purchased 19,900 shares of the firm’s stock in a transaction on Tuesday, May 10th. The stock was bought at an average cost of $7.72 per share, for a total transaction of $153,628.00. Following the completion of the purchase, the chief executive officer now owns 971,921 shares in the company, valued at approximately $7,503,230.12. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Aldrich purchased 20,000 shares of the firm’s stock in a transaction on Wednesday, May 11th. The stock was acquired at an average price of $7.64 per share, with a total value of $152,800.00. Following the completion of the purchase, the director now owns 604,185 shares of the company’s stock, valued at approximately $4,615,973.40. The disclosure for this purchase can be found here.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.